The drugmaker Johnson & Johnson says it will delay the rollout of its COVID-19 vaccine in Europe. That's after health authorities in the US moved to suspend the use of the shot, due to health concerns. More than 6.8 Million doses of the Johnson & Johnson vaccine have already been administered in the US, most with no or very mild side effects. But US health bodies are now investigating unusual blood clots that occured in six women under the age of 50. The cases appear similar to a rare clotting disorder European authorities say could be linked to the AstraZeneca vaccine.
Subscribe: https://www.youtube.com/user/deutschewelleenglish?sub_confirmation=1
For more news go to: http://www.dw.com/en/
Follow DW on social media:
►Facebook: https://www.facebook.com/deutschewellenews/
►Twitter: https://twitter.com/dwnews
►Instagram: https://www.instagram.com/dwnews
Für Videos in deutscher Sprache besuchen Sie: https://www.youtube.com/dwdeutsch
#J&J # vaccine #bloodclot
Subscribe: https://www.youtube.com/user/deutschewelleenglish?sub_confirmation=1
For more news go to: http://www.dw.com/en/
Follow DW on social media:
►Facebook: https://www.facebook.com/deutschewellenews/
►Twitter: https://twitter.com/dwnews
►Instagram: https://www.instagram.com/dwnews
Für Videos in deutscher Sprache besuchen Sie: https://www.youtube.com/dwdeutsch
#J&J # vaccine #bloodclot
- Category
- Europe
- Tags
- Johnson & Johnson, J&J, J&J vax
Sign in or sign up to post comments.
Be the first to comment